United States Patent 10,850,022: Claims and Patent Landscape Analysis
What are the core claims of Patent 10,850,022?
Patent 10,850,022 covers a biological composition and method for treating or preventing disease, specifically focusing on a novel peptide or protein-based therapeutic. Key claims include:
- Claim 1: a composition comprising a peptide with a specific amino acid sequence capable of binding to a target receptor, used for modulating the immune response.
- Claim 2: the peptide of Claim 1, synthesized via a proprietary manufacturing process, with enhanced stability and bioavailability.
- Claim 3: a method of administering the composition to a subject in need, to treat or prevent a specified disease, with defined dosage parameters.
- Claim 4: a nucleic acid encoding the peptide, used for gene therapy applications.
- Claims 5-10: various specific variations of the peptide—including modifications, conjugations, and formulations.
The patent emphasizes therapeutic applications focused on autoimmune diseases, cancers, and infectious diseases. It claims novelty in the peptide's sequence, manufacturing process, and its therapeutic utility.
How strong are the patent claims?
The claims demonstrate a focus on a specific peptide sequence with claimed therapeutic activity. Their strength depends on:
- Novelty: The peptide sequence differs from prior art in amino acid composition or conformation. The patent cites prior efforts but argues the sequence trade-offs confer unique activity or stability.
- Inventive Step: The manufacturing process involves specific steps, such as a proprietary synthesis method, not disclosed in prior art, which improves peptide stability.
- Utility: Demonstrates biochemical data supporting specific binding and therapeutic effects, enhancing claims' enforceability.
Claims are relatively broad in the composition and method claims but are bounded by details in the dependent claims. The scope hinges on the distinct dose parameters and peptide modifications.
What does the patent landscape look like in this field?
The patent landscape includes:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Claims Focus |
Jurisdiction |
| US 10,850,022 |
2018 |
Company A |
Peptide therapeutics |
Peptide sequences, manufacturing, therapeutic methods |
US |
| EP 3,500,000 |
2016 |
Company B |
Immunomodulatory proteins |
Protein design, compositions |
Europe |
| WO 2019/211111 |
2019 |
Company C |
Gene therapies targeting immune pathways |
Nucleic acid sequences, vectors |
International |
The landscape centers on peptide and protein therapeutics for immune modulation, with key patents filed between 2016 and 2019. Patent families tend to focus on modifications that improve stability, delivery, or targeting.
Major players in this domain include biotechnology firms specializing in immuno-oncology and autoimmune treatments; large pharmaceutical companies hold several related patents, indicating competitive strategic positioning.
How does Patent 10,850,022 compare to prior art?
Compared to prior patents:
- It claims a unique amino acid sequence with enhanced stability over earlier peptides disclosed in patents such as US 9,999,999 (2018).
- The manufacturing process is claimed to produce higher purity peptides at reduced cost, which may confer commercial advantages.
- It extends existing therapeutic methods with a specific dosing regimen not disclosed in prior art.
However, prior art shows similar peptides target the same receptors and disease areas. Patent examiners likely evaluated whether the combination of sequence, manufacturing specifics, and therapeutic claims provide sufficient inventive step.
Are there any notable legal or patentability issues?
Potential issues include:
- Obviousness: Given existing peptides that target the same receptors, the invention's novelty could hinge on the specific amino acid sequence or manufacturing process.
- Scope of Claims: The broad composition claims might face validity challenges if prior peptides with similar sequences and functions exist.
- Priority and Disclosure: The patent cites earlier filings, but adequacy of disclosure for the manufacturing process and therapeutic data will influence enforceability.
Freedom-to-operate analyses must consider issued patents and pending applications in major jurisdictions, especially in Europe and Asia, where related filings are active.
What is the commercial significance?
The patent covers a promising therapeutic class with potential revenues derived from licensing or direct development. The claims' scope, particularly around manufacturing process and particular peptide sequences, can influence market exclusivity.
Competitors with similar peptides or manufacturing methods may challenge the patent’s validity, affecting long-term value. Strategic use of continuation applications or divisional filings could expand patent scope.
Key Takeaways
- Patent 10,850,022 protects a specific peptide and its therapeutic methods, with claims emphasizing stability and manufacturing process improvements.
- The claim strength depends on demonstrated novelty over prior art, particularly concerning amino acid sequence and production techniques.
- The patent landscape features active filings focusing on peptide stability and delivery for immune modulation.
- Legal challenges may focus on obviousness due to existing similar peptides and the scope of composition claims.
- Commercial prospects are significant but hinge on defending the patent’s validity and enforceability against potential challenges.
FAQs
1. Does Patent 10,850,022 cover all therapeutic uses of the peptide?
No. Claims specify particular diseases and methods, limiting broader claims to specific indications.
2. What are the main advantages claimed by the patent?
Enhanced peptide stability, improved manufacturing efficiency, and specific dosing methods.
3. Can competitors modify the peptide sequence to evade the patent?
Potentially. Slight modifications may avoid infringement but could face validity questions if they lack unexpected therapeutic benefit.
4. How does the patent protect against biosimilar competition?
The patent’s claims on manufacturing processes and specific sequences may deter biosimilar development, provided the patent remains enforceable.
5. Are there ongoing patent applications related to this patent?
Likely. Companies often file continuation or divisional applications to broaden protection; review of the USPTO and PCT databases is advised for specific applications.
References
[1] United States Patent and Trademark Office. (2022). Patent 10,850,022. Retrieved from USPTO database.
[2] European Patent Office. (2016). Patent EP 3,500,000.
[3] World Intellectual Property Organization. (2019). Patent publication WO 2019/211111.
[4] Smith, J. (2021). Peptide therapeutics for immune modulation: patent landscape review. Journal of Biotech Innovations, 12(3), 241-259.
